Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of SYHA1805 in Healthy Chinese Adults
NCT04977570Phase 1Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jul 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in Nonalcoholic steatohepatitis (NASH) comparing SYHA1805 with Placebo (2 arms). Primary endpoint: Safety and tolerability of multiple-dose of SYHA1805 at Day 28. Status: unknown.
02
Drugs
SYHA1805
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04977570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04977570.